Cannabis Compound Interactions May Shape Therapeutic Effects, but the “Entourage Effect” Remains Unproven
A 2024 review in Molecules examines how cannabinoids, terpenes, and flavonoids in Cannabis sativa may interact to influence biological effects. The authors focus particularly on neuroinflammation and neuroprotection, while emphasizing that much of the evidence remains preclinical and that the proposed “entourage effect” has not been firmly established in clinical research.
The review, “The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects”, describes cannabis as a chemically complex plant rather than a source of only THC and CBD. Its other constituents include minor cannabinoids, aromatic terpenes such as myrcene, limonene, pinene, and linalool, and plant pigments known as flavonoids.
The idea that these compounds can modify one another’s effects is commonly called the entourage effect. In its broadest form, the hypothesis proposes that combinations of cannabis constituents may produce additive, synergistic, or otherwise different effects from isolated compounds. Interactions could occur through several pathways, including activity at different molecular targets, changes in drug metabolism, or alterations in how compounds are absorbed and distributed in the body.
Cannabinoids can influence the endocannabinoid system, which includes CB1 and CB2 receptors as well as enzymes and signaling molecules involved in regulating pain, inflammation, mood, and immune activity. Terpenes have their own pharmacological properties and may affect targets involved in inflammation, anxiety, pain, and nervous-system function. The review highlights beta-caryophyllene as one example: it has been reported to act as a selective CB2 receptor agonist in preclinical research.
Flavonoids have received less research attention than cannabinoids and terpenes. Cannabis-derived flavonoids called cannflavins are of particular interest because laboratory studies have associated them with anti-inflammatory activity. A 2020 scoping review of cannflavin research found promising results in cell and other preclinical models, but also noted that limited extraction yields and a lack of clinical studies have slowed development. More recent laboratory work has likewise examined cannflavin A’s effects on inflammatory signaling in human macrophage cells, rather than in patients.
The evidence for compound interactions is not consistent. Some experiments have reported enhanced biological activity when cannabinoids and terpenoids are combined, including in cell-based studies. Other investigations have found no meaningful effect of common cannabis terpenes on THC activity at human CB1 and CB2 receptors. For example, the 2019 study “Absence of Entourage” found that several tested terpenoids did not modify THC’s functional activity at those receptors, while a separate study reached similar conclusions for terpene mixtures. These findings do not rule out interactions through other biological pathways, but they show why broad claims about synergy should be treated cautiously.
The review argues that future studies should test defined combinations and ratios of cannabinoids, terpenes, and flavonoids rather than treating cannabis as a single, uniform product. Such work could help determine whether particular chemical profiles are associated with different effects or side-effect patterns. It could also support the development of standardized formulations instead of relying on strain names or assumptions based primarily on THC concentration.
However, the review does not demonstrate that full-spectrum cannabis products are clinically superior to purified cannabinoids. Much of the cited evidence comes from cell cultures, animal models, chemical analyses, or theoretical pharmacology. Results from those settings may not translate directly to safe or effective treatments in humans, and interactions could be beneficial, neutral, or unfavorable depending on the compounds and doses involved.
Progress will depend on better-characterized cannabis preparations, reproducible laboratory methods, well-designed clinical trials, and clearer safety data. In the United States, regulatory requirements and the legal status of cannabis have historically complicated research; the Drug Enforcement Administration’s current marijuana rescheduling proceedings illustrate that the federal framework remains in transition.
For now, the entourage effect is best understood as a research hypothesis rather than an established therapeutic principle. The chemical diversity of cannabis may offer opportunities for new medicines, but identifying useful combinations will require evidence that distinguishes genuine synergy from simple additive effects, differences in dosing, or marketing claims.
